title: [Autologous peripheral blood stem cells transplantation in treatment of 62 cases of lower extremity ischemic disorder].
abstract: OBJECTIVE
  To observe the clinical efficacy of autologous peripheral blood stem cells (PBSC) transplantation in 62 cases with ischemic lower extremity disorder.
  
  
  METHODS
  Totally 62 patients with 34 cases of diabetic foot and 28 cases of various lower extremity ischemic disorders received recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) 450 - 600 microg/d by hypodermic injection for 5 days to mobilize stem cells. On the sixth day, PBSC were collected by COBE 6.1 Spectra Version with an amount of 82 - 148 ml; the number of mononuclear cells (MNC) is (718.2 - 224.6) x 10(9)/L. CD34+ cells were tested. The PBSC were injected into the ischemic lower extremity and foot intramuscularly at 3 cm x 3 cm distance. The clinical and laboratory findings were monitored from first day to 24th week.
  
  
  RESULTS
  In 62 patients with PBSC transplantation, free of severe pain was found in 54 cases (87.1%) from 7 to 30 days, improvement of foot cool feeling in 56 patients (90.3%) from 7 to 30 days, improvement of foot ulcer in 16 cases (40.0%) from 4 to 16 weeks. Ankle/brachial index (ABI) increased in 12 cases (34.3%), TcPO2 improved in 26 cases (42.3%). Digital subtraction angiographic scores were performed in 5 patients after 8 - 12 weeks, there was formation of new collateral vessels. No related complication or adverse effect was observed except in 2 patients with diabetic foot and cerebral infarction exacerbation of symptoms during the process of stem cells mobilization in all process.
  
  
  CONCLUSIONS
  Autologous PBSC transplantation might be a safe and effective method for lower extremity ischemic disorder. It could improve the quality of life of many patients as amputation of lower extremity or foot might be avoided.
authors.affiliation: Cell Treatment Center, PLA 463 Hospital, Shenyang 110042, China. YXF463@Hotmail.com
authors.forename: Xiao-feng
authors.initials: XF
authors.lastname: Yang
authors.forename: Yan-xiang
authors.initials: YX
authors.lastname: Wu
authors.forename: Hong-mei
authors.initials: HM
authors.lastname: Wang
authors.forename: Yi-feng
authors.initials: YF
authors.lastname: Xu
authors.forename: Xin
authors.initials: X
authors.lastname: Lü
authors.forename: Yi-bin
authors.initials: YB
authors.lastname: Zhang
authors.forename: Fa
authors.initials: F
authors.lastname: Wang
authors.forename: Yue
authors.initials: Y
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001162:Arteriosclerosis Obliterans / Q000628:therapy; D017719:Diabetic Foot / Q000628:therapy; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D007511:Ischemia / Q000628:therapy*; D035002:Lower Extremity / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D011994:Recombinant Proteins; D014182:Transplantation, Autologous
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor